Podcasts about Cardiology

"10 Key Questions Facing Medicare Advantage" is the subject for our Medicare Advantage Minute. More trouble ahead? This is the reason we spend time in every episode warning listeners of MA plan dangers! In "Your Medicare Benefits 2024" we learn about how Emergency Department Services are reimbursed by Medicare. As usual they ignore the fact that my clients, and all responsible Medicare participants, will have acquired a Medicare supplement plan to enhance the Medicare reimbursement amount. Average earnings of Medical Doctors by specialty in an interesting way to decide whether you could have chosen a more lucrative path in life! The lowest earning specialties are: Public Health & Preventive Medicine (lowest at $257K per year) Pediatrics and Family Medicine. Highest earners are: Orthopedic & Ortho Surgery ($543K per year) followed by Radiology, Plastic Surgery and Cardiology out of a total of 29 different branches of medicine.   Contact me at: DBJ@MLMMailbag.com (Most severe critic: A+)                   Visit us on: BabyBoomer.ORG Inspired by: "MEDICARE FOR THE LAZY MAN 2025; Simplest & Easiest Guide Ever!" on Amazon.com. Return to leave a short customer review & help future readers. Official website: https://www.MedicareForTheLazyMan.com.

Send us a textShort Summary: Heart health and the ketogenic diet, with expert insights from a cardiologist and researcher.About the guest: Matthew Budoff, MD, is a preventive cardiologist and professor of medicine at UCLA School of Medicine.Note: Podcast episodes are fully available to paid subscribers on the M&M Substack and everyone on YouTube. Partial versions are available elsewhere. Transcript and other information on Substack.Episode Summary: Dr. Matthew Budoff discusses cholesterol, heart disease, and his study on the ketogenic diet's impact on lean, metabolically healthy individuals with high LDL cholesterol. He explains LDL, HDL, and triglycerides, debunking myths about their direct link to heart disease, and emphasizes the importance of coronary calcium scans to assess plaque buildup. Budoff also covers statins, dietary cholesterol, and personalized heart health strategies.Key Takeaways:LDL cholesterol is not a definitive predictor of heart disease; plaque buildup, assessed via coronary calcium scans, is a better indicator.Lean metabolically healthy people on a ketogenic diet may have high LDL without increased plaque progression after one year.Coronary calcium scans, costing ~$100, are recommended for men around age 40 and women around 45-50 to evaluate heart disease risk.Statins effectively lower LDL and can reverse soft plaque, but may be overprescribed for those without plaque buildup.Dietary cholesterol has minimal impact on blood cholesterol, as the liver produces ~85% of it.Ketogenic diet can aid weight loss & diabetes control but may cause high LDL in some lean individuals, known as lean mass hyper-responders.Plaque progression depends more on existing plaque than LDL levels in metabolically healthy ketogenic diet followers.Heart health varies widely due to genetics and other unknown factors, underscoring the need for personalized assessments.Related episode:M&M #158: Ketosis & Ketogenic Diet: Brain & Mental Health, Metabolism, Diet & Exercise, Cancer, Diabetes | Dominic D'AgoSupport the showAll episodes, show notes, transcripts, etc. at the M&M Substack Affiliates: Lumen device to optimize your metabolism for weight loss or athletic performance. Use code MIND for 10% off. Readwise: Organize and share what you read. Athletic Greens: Comprehensive & convenient daily nutrition. Free 1-year supply of vitamin D with purchase. KetoCitra—Ketone body BHB + potassium, calcium & magnesium, formulated with kidney health in mind. Use code MIND20 for 20% off any subscription. MASA Chips—delicious tortilla chips made from organic corn and grass-fed beef tallow. No seed oils or artificial ingredients. Use code MIND for 20% off. For all the ways you can support my efforts

The FAME 3 trial 5-year results, TAVR at 5 years, pacers after TAVR, and mavacamten not a wonder drug are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I FAME 3 at Five Years Stents as Good as Surgery for Triple-Vessel Disease https://www.medscape.com/viewarticle/noninvasive-stents-good-surgery-triple-vessel-disease-2025a10007l4 Main trial NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2112299 Circulation 3-years https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.065770 5-year results Lancet 10.1016/S0140-6736(25)00505-7 https://linkinghub.elsevier.com/retrieve/pii/S0140673625005057 II TAVR in Low-Risk Patients at 5 years 5-Year TAVR, Surgery Outcomes Similar in Low-Risk Patients https://www.medscape.com/viewarticle/5-year-tavr-surgery-outcomes-similar-low-risk-patients-2025a10007zl EVOLUT Low-Risk 5 years https://www.jacc.org/doi/10.1016/j.jacc.2025.03.004 EVOLUT Editorial – We're Halfway There https://www.jacc.org/doi/10.1016/j.jacc.2025.03.428 PARTNER 3 Low-Risk https://www.nejm.org/doi/full/10.1056/NEJMoa2307447 NOTION at 5 years https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.036606 III The Matter of Pacemakers After TAVI JACC IV Study Badertscher https://www.jacc.org/doi/10.1016/j.jcin.2025.03.028 Assessing the quality of reporting of harms in randomized controlled trials published in high impact cardiovascular journals   IV Mavacamten Looks to Have Specific Indications EXPLORER HCM 10.1016/S0140-6736(20)31792-X External Link VALOR HCM https://jamanetwork.com/journals/jamacardiology/fullarticle/2809050 BMS Press Release https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Provides-Update-on-Phase-3-ODYSSEY-HCM-Trial/ FINAL THOUGHTS PRAGUE 25 https://bmjopen.bmj.com/content/12/6/e056522 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Eli Lilly will start a lcinical trial for tirzepatide for people with type 1 diabetes, more details on Dexcom's 15 day G7 sensor, Ozepmic pill form tested, type 5 diabetes identified and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Our top story this week.. Eli Lilly takes the first steps toward getting tirzepatide approved for people with type 1 diabetes. Tirzepatide is sold under the brand names Mounjaro for type 2 and Zepbound for obesity. The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or are overweight. Participation in the study will last about 49 weeks. Official Title A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Tirzepatide Once Weekly Compared to Placebo in Adult Participants With Type 1 Diabetes and Obesity or Overweight This is a big deal because, even though many people with type 1 are able to get a prescription for tirzepatide, it's not approved for T1D and so insurers won't usually cover it.   https://clinicaltrials.gov/study/NCT06914895 XX The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a new study finds, even though there's little information on the drugs' safety and effectiveness for the condition. The family of medications called GLP-1 receptor agonists includes drugs like Wegovy, Zepbound, Ozempic, Mounjaro and Victoza. But the clinical trials of these medications specifically excluded people with type 1 diabetes, who are dependent on the hormone insulin to survive because they can't make enough of their own. Drugmakers feared that using the GLP-1 medications with insulin might raise the chance of dangerously low blood sugar events, or hypoglycemia, and were unwilling to take the risk of studying them in people with type 1.   For the study, which was published last month in the journal Diabetes, Obesity, and Metabolism, researchers at Johns Hopkins University reviewed the medical records of more than 200,000 people with type 1 diabetes from 2008 to 2023. They grouped the data in three-year periods, starting with October 2008 to September 2011 and ending with October 2020 to September 2023. GLP-1 medication use spiked, as well. Among adults with the highest category of obesity, about 4% used GLP-1 medications in 2008, and 33% did by 2023 – an 800% increase. But these are anecdotal reports and may not reflect instances in which people have side effects or complications like low blood sugar, which can be life-threatening. But Shin says what's really needed is information from randomized, double-blinded studies, in which participants are followed forward in time and given either a drug or a placebo. https://www.cnn.com/2025/04/09/health/glp-1-type-1-diabetes-study/index.html   XX Later this month the FDA will conduct a final meeting regarding a new, investigational compound (sotagliflozin) soda-GLIFF-a-zin that has been shown to Improve QoL and Reduce Long-term Complications for people with type 1 diabetes (T1D). The patient advocacy group Taking Control of Your Diabetes (TCOYD.org) is working to inform the T1D community about sotagliflozin - and to encourage people to sign a Change.org petition directed towards FDA.  Last fall, the FDA declined to approve sotagliflozin due to concerns about a potential increased risk of diabetic ketoacidosis (DKA), despite this being a condition that people with T1D on insulin face and manage daily. While TCOYD respects FDA's caution, the group stands by T1D patients and their physicians who, as a team, balance risks and benefits every day. https://tcoyd.org/petition/ XX Dexcom receives FDA approval for it's G7 with 15 day wear. We have an interview with Chief Operating Officer Jake Leach coming up on Tuesday – we talk about the planned roll out of this sensor, what else has changed, and the fine print in the press release – it says    “A study was conducted to assess the sensor life where 73.9% of sensors lasted the full 15 days. When using the product per package labeling, approximately 26% of sensors may not last for the full 15 days.   https://investors.dexcom.com/news/news-details/2025/Dexcom-G7-15-Day-Receives-FDA-Clearance-the-Longest-Lasting-Wearable-and-Most-Accurate-CGM-System/default.aspx?utm_source=www.diabetech.info&utm_medium=referral&utm_campaign=dexcom-g7-15-day-sensor-gets-fda-cleared-but-will-it-actually-last-that-long   XX Glucotrack is joining something called  FORGETDIABETES bionic pancreas initiative, - this is an European Union project that aims to develop a long-term automated insulin delivery system for type 1 diabetes patients. Glucotrack's Continuous Blood Glucose Monitor (CBGM) will be integrated into the system to provide real-time glucose readings. The initiative's goal is to create a bionic invisible pancreas that eliminates the need for therapeutic actions and reduces psychological burden.   The architecture of BIP encompasses a ground-breaking, lifelong lasting implanted ip glucose nanosensor; a radically novel ip hormone delivery pump, with unique non-invasive hormone refill with a magnetic docking pill and non-invasive wireless battery recharge; an intelligent closed-loop hormone dosing algorithm, optimized for ip sensing and delivery, individualized, adaptive and equipped with advanced self-diagnostic algorithms.     Pump refilling through a weekly oral recyclable drug pill will free T1D subjects from the burden of pain and awkward daily measurement and treatment actions. Wireless power transfer and data transmission to cloud-based data management system round-up to a revolutionary treatment device for this incurable chronic disease. key feature of BIP is to be fully-implantable and life-long lasting thanks to novel biocompatible and immune-optimized coatings guaranteeing long-term safety and stability https://www.stocktitan.net/news/GCTK/glucotrack-to-participate-in-forgetdiabetes-a-prominent-european-cjjldjb0dq7h.html XX A newly recognised form of diabetes, called Type 5, was announced this week at the World Congress of Diabetes 2025. A global task force will investigate this less-understood condition, which differs from Type 1 and Type 2 diabetes. Type 5 diabetes affects people who are underweight, lack a family history of diabetes and do not show the typical symptoms of Type 1 or Type 2 diabetes. The condition was first observed in the 1960s and referred to as J-type diabetes, after being detected in Jamaica. It was classified by the World Health Organisation in 1985, but removed in 1998 due to lack of physiological evidence. At the time, experts believed it to be a misdiagnosed case of Type 1 or 2 diabetes. New research has since confirmed that Type 5 is different. https://economictimes.indiatimes.com/news/new-updates/a-new-type-of-diabetes-has-been-found-by-scientists-and-it-doesnt-show-the-typical-symptoms-of-type-1-or-type-2/articleshow/120276658.cms?from=mdr   XX Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. A new clinical trial, co-led by endocrinologist and diabetes specialist John Buse, MD, PhD, and interventional cardiologist Matthew Cavender, MD, MPH, at the UNC School of Medicine, has demonstrated that the oral form of semaglutide significantly lowers the risk of cardiovascular events in individuals with type 2 diabetes, atherosclerotic cardiovascular disease, and/or chronic kidney disease. Results from the rather large, international trial were published in the New England Journal of Medicine and presented at the American College of Cardiology's Annual Scientific Session & Expo in Chicago, Illinois.     The effect of oral semaglutide on cardiovascular outcomes was consistent with other clinical trials involving injectable semaglutide, but more trials are needed to determine if one method may be more effective than the other at reducing major cardiovascular events. https://scitechdaily.com/new-pill-form-of-semaglutide-shows-major-benefits-for-people-with-diabetes/ XX April 14 (UPI) -- The U.S. Food and Drug Administration on Monday warned consumers and pharmacies that fake versions of Ozempic, a drug to treat Type 2 diabetes, have been found in the United States. Novo Nordisk, the Danish-headquartered manufacturer, informed the FDA on April 3 that counterfeit 1-milligram injections of semaglutide were being distributed outside its authorized supply chain. The FDA and Novo Nordisk are testing the fake products to identify whether they're safe. Patients are asked to obtain Ozempic with a valid prescription through state-licensed pharmacies and check the product for any signs of counterfeiting. People in possession of the fake product are urged to call Novo Nordisk customer care at 800-727-6500 Monday through Friday from 8:30 a.m. to 6 p.m. EDT and report it to the FDA's criminal activity division's website. Side effects can be reported to FDA's MedWatch Safety Information and Adverse Event Reporting Program (800-FDA-1088 or www.fda.gov/medwatch) as well as to Novo Nordisk, at 800-727-6500. https://www.upi.com/Health_News/2025/04/14/FDA-fake-Ozempic-drugs-Novo-Nordisk/6841744666854/ XX Can a digital lifestyle modification program reduce diabetes risk? A new study shows that the lifestyle intervention significantly reduced 10-year diabetes risk among prediabetics by nearly 46% and increased the diabetes remission rate, highlighting the importance of lifestyle changes. However, the study was not a randomized trial, and participation in the lifestyle intervention was voluntary, which may introduce selection bias. The study evaluated 133,764 adults, categorizing them as diabetic (7.5%), prediabetic (36.2%), and healthy (56.3%), based on fasting glucose and HbA1c levels. https://www.news-medical.net/news/20250414/Digital-lifestyle-program-cuts-diabetes-risk-by-4625-in-prediabetics-study-of-130k2b-adults-reveals.aspx XX Chrissy Teigan is speaking out about her son's type 1 diagnosis – teaming up with Sanofi to encourage people to screen early for Type 1 diabetes.   Teigen got a crash course in the risks of undiagnosed Type 1 diabetes when her 6-year-old son, Miles, was hospitalized with complications of the autoimmune disease last year. The family knew nothing about Type 1 diabetes when Miles was diagnosed during an unexpected medical emergency, Teigen said in a Tuesday announcement. “We were confused and scared when Miles was first diagnosed,” she said in a statement. “There is no doubt in my mind that knowing in advance would have made a positive impact for Miles, me, and our entire family. I want everyone to hear me when I say: stay proactive and talk to your doctor about getting yourself or your loved ones screened for type 1 diabetes today!”   Teigen shared her family's story in a two-minute video on ScreenForType1.com, a Sanofi website that discusses how to get screened for the condition. Miles' diagnosis made Teigen feel like she “went from a mom to a doctor overnight,” she said. That experience is why Teigen said she is “begging you: Do this one thing, and screen yourself and your family for Type 1 diabetes.” https://www.fiercepharma.com/marketing/sanofi-signs-chrissy-teigen-diabetes-screening-campaign XX Dr. Richard Bernstein – best known for his advocacy around low carb diets for people with diabetes – died this week at the age of 90. Born in 1934 in Brooklyn, New York, he was diagnosed with type 1 at age 12. In the 1970s he adapted a blood glucose monitor for home use and helped pioneer home glucose monitoring. He published multiple books on Diabetes including the #1 selling Diabetes book on Amazon.Com “Dr. Bernstein's Diabetes Solution: A Complete Guide to Achieving Normal Blood Sugars” and “Diabetes Type II: Living a Long, Healthy Life Through Blood Sugar Normalization”.  He practiced and saw patients right up until his death.

This week we review a study assessing the impact of bundle branch block (BBB) on exercise tolerance amongst the single ventricle Fontan patient cohort. Why would this be associated with worse outcomes for exercise? How should the cardiologist use this datum of BBB in a single ventricle patient to inform clinical decision making in this patient group? Why is cardiac resynchronization therapy so challenging in this patient group? Dr. Omar Meziab of The University of Arizona shares his deep insights this week. https://doi.org/10.1007/s00246-024-03500-1

Click here for the Revenue Recovery cheat sheet: https://hubs.ly/Q03hvhqw0 Welcome to the seventh episode of our HeartTalk podcast series, Revenue Recovery. Host Melanie Lawson, MS, speaks with Linda Gates-Striby, CCS-P, ACS-CA, Revenue Cycle Solutions consultant. They dive into how to appropriately capture Prolonged Care services and offer practical examples for your organization.  Guest Bio:Linda Gates-Striby, CCS-P, ACS-CAMedAxiom Consultant, Revenue Cycle Solutions Linda Gates-Striby has worked in the medical field for over 30 years and has specialized in cardiology coding and revenue cycle for 25 years. Her clinical experience includes work in the heart stations and coronary intensive care units as well as working as an EMT for a level one trauma center. As a MedAxiom Revenue Cycle Solutions consultant, Linda provides cardiovascular programs across the country with operational expertise, implementation strategies and simplification for often complex initiatives to minimize risk and maximize revenue. Linda, who has spent the past 30 years working as a specialist in compliance, revenue cycle and quality with a large cardiology and multi-specialty practice, is also the director of quality assurance with Ascension Medical Group in Indiana. Linda is a sought-after speaker and consultant and has conducted numerous national educational sessions focused on documentation, coding, auditing and revenue cycle improvement for clinicians, coders and administrators across the nation. Linda serves as a non-physician member of the American College of Cardiology's coding work group and publications subcommittee and has also served on the coding committee for the Heart Rhythm Society. Linda served as the cardiology chair on the Board of Advanced Medical Coding, lead the development of the Advanced Cardiology and Specialty Cardiology Certification examinations, and was the technical editor for cardiology-focused newsletters. Linda has served as an Independent Review Organization auditor for Office of Inspector General Corporate Integrity Agreements, and as an expert witness on behalf of cardiology practices.

Tuesday, April 15 -  Host Doug Stephan and Dr. Ken Kronhaus of Lake Cardiology (352-735-1400) cover a number of topics affecting our health. First up, Doug and Dr. Ken start with a recap of Doug's visit to Dr. Ken's practice in Mount Dora, FL. Next up, the biggest topics in the news of health and medicine, including how lowering bad cholesterol also lowers the risk of developing dementia, why you should learn what your cholesterol readings should be (because it's not one-size-fits-all), why you should talk to your doctor about your LPa numbers (and what that means), and a number of other therapies to help maintain your best cholesterol (good and bad) levels for optimum health. Then, Doug waves his HIPAA rights to share insight of how many of us forget to look at things in our lives affecting our health, like stress. Mental stress, poor sleep, and obesity are the three main culprits contributing to plaque buildup, high cholesterol, and poor overall health. The first step to better health is getting those three things under control. Website: GoodDayHealthShow.com Social Media: @GoodDayNetworks

. To learn more about this program, please click here.

Mark Goddard, Vice President of Clinical Services at InfoBionic.Ai, a leading authority in cardiac remote monitoring. A registered nurse with over 20 years of experience in clinical electrophysiology, Mark has pioneered service lines across ambulatory ECG, cardiac event monitoring, mobile telemetry and heart failure management in hundreds of institutions. He's also a certified Clinical Cardiac Device Specialist with deep knowledge of subcutaneous monitoring and AI-assisted diagnosticsIn this episode, we explore how AI and real-time ECG data are revolutionising arrhythmia detection, heart failure prediction and patient engagement especially for high-risk groups like those with A-Fib. Mark shares practical insights from the front lines of cardiac care, how to tell genuine innovation from AI hype and why the future of diagnostics may lie beyond traditional heart monitoring. We also cover clinical implementation challenges, device design for older populations and the fine line between wellness tracking and medical-grade careTimestamps:[00:00:27] AI-Powered ECG: From Novelty to Necessity[00:03:28] How Clinicians Are Separating Hype from Reality[00:05:07] Why Near Real-Time Beats Traditional ECG Monitoring[00:08:49] A-Fib and the Global Data Gap[00:11:36] When Good Tech Goes Bad: Early Pacemaker Mistakes[00:13:30] Hospitals, Homes and the Future of Cardiac Care[00:19:59] AI vs Machine Learning: What's the Real Difference?Get in touch with Mark - https://www.linkedin.com/in/mark-goddard-035ab427/ Get in touch with Karandeep Badwal - https://www.linkedin.com/in/karandeepbadwal/ Follow Karandeep on YouTube - https://www.youtube.com/@KarandeepBadwalSubscribe to the Podcast

The TAP-IT, STRIDE, FreshUP, and SINGLE SHOT CHAMPION trials are discussed by John Mandrola, MD, in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I TAP IT  TAP IT trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.124.073521 II STRIDE LANCET Ref 10.1016/S0140-6736(25)00509-4 SUMMIT HF https://www.nejm.org/doi/full/10.1056/NEJMoa2410027 III FRESH UP No Need to Restrict Fluids in Stable Heart Failure https://www.medscape.com/viewarticle/no-need-restrict-fluids-stable-heart-failure-2025a10008bu Nature (Trial) https://www.nature.com/articles/s41591-025-03628-4 SODIUM HF https://pubmed.ncbi.nlm.nih.gov/35381194/ IV PFA for AF ablation SINGLE SHOT CHAMPION https://www.nejm.org/doi/full/10.1056/NEJMoa2502280 ADVENT https://www.nejm.org/doi/full/10.1056/NEJMoa2307291 Foy et al https://pmc.ncbi.nlm.nih.gov/articles/PMC11852674/ MANIFEST REDO Study https://doi.org/10.1093/europace/euaf012 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

In this replay episode from 2023, we return to the world of ACHD when we review a recent German research paper on the prevalence of PTSD symptoms amongst the ACHD patient group. How common is this type of symptom observed in the ACHD patient group? What contributes to the high prevalence (17-20.5%) described in this work? What are the benefits of 'embedding' a mental health care worker in the ACHD clinic/program? What strategies can be employed in pediatric cardiology to potentially mitigate PTSD symptoms in our future ACHD patients? These are amongst the many topics reviewed this week with the former Mount Sinai ACHD program clinical social worker, Ms. Meredith Kalbacker who also comments on this week's work. DOI: 10.1016/j.amjcard.2023.06.087For those interested, the book referenced by Ms. Kalbacker, Healing Hearts and Minds, can be purchased on Amazon:https://www.amazon.com/Healing-Hearts-Minds-Holistic-Congenital/dp/0197657281

First, we talk to The Indian Express' Legal Affairs Editor Apurva Vishwanath about the Supreme Court's ruling on Tamil Nadu governor RN Ravi withholding assent to 10 bills of the state assembly and the limits to the role of a Governor.Next, we talk to The Indian Express' Anonna Dutt about a study conducted by the Institute of Cardiology at Madras Medical College which has proposed a model by way of which necessary medical care can be provided to a heart attack patient even in remote rural areas. (13:02)Lastly, we speak about the Indians who were targeted by the Israeli spyware Pegasus in a 2019 WhatsApp hacking campaign. (22:36)Produced and hosted by Niharika Nanda and Shashank BhargavaEdited and mixed by Suresh Pawar

Send us a textDr. Michael Koren shares insights from his presentation at the American College of Cardiology meeting in Chicago about a groundbreaking oral PCSK9 inhibitor that could lower cholesterol by 80% when combined with a statin. The development represents a significant advancement in treatment options for the 20% of patients who don't respond adequately to statins alone or experience statin intolerance. They also chat about Chicago and the importance of things in moderation.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Returning for a second study this month, the JHLT Digital Media Editors invite first author Charlotte Van Edom to discuss the paper, “Apixaban plasma levels in patients with HeartMate 3 support.” As a cardiologist in training and a PhD candidate at the University Hospitals Leuven in Belgium, Van Edom's work focuses on hemocompatibility and mechanical circulatory support, covering both short-term and long-term support. The episode explores: The evolution of the use and understanding of direct oral anticoagulants (DOACs) during LVAD support, including the increased focus on Factor Xa inhibitors Encouraging findings from the study and what clinical practices might need to change if introducing apixaban Additional studies exploring DOACs in LVAD patients For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt. Treat or research pulmonary vascular diseases? Check out the first April episode for a study on sotatercept in PAH patients. Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

A panel discussion of a Presidential Advisory from the American Heart Association that outlines the importance of funding for scientific research and the need for a robust National Institutes of Health. This podcast is intended for healthcare professionals only. To read a transcript or to comment, visit https://www.medscape.com/author/bob-harrington INCLUDE URLS and full titles for some of the pertinent studies cited. You may also like: Principles for the Future of Biomedical Research in the United States and Optimizing the National Institutes of Health: A Presidential Advisory From the American Heart Association https://doi.org/10.1161/cir.0000000000001319 The Role of Public-Sector Research in the Discovery of Drugs and Vaccines." https://www.nejm.org/doi/full/10.1056/NEJMsa1008268 Comparison of Research Spending on New Drug Approvals by the National Institutes of Health vs the Pharmaceutical Industry, 2010-2019 https://pubmed.ncbi.nlm.nih.gov/37115539/ Hear John Mandrola, MD's summary and perspective on the top cardiology news each week on This Week in Cardiology https://www.medscape.com/twic Questions or feedback, please contact news@medscape.net

This episode covers: Cardiology This Week: A concise summary of recent studies Current indications for pulmonary vein isolation Conduction system pacing EHRA 2025 scientific highlights Host: Susanna Price Guests: Haran Burri, Isabel Deisenhofer, Helmut Puererfellner, Emma Svennberg Want to watch that episode? Go to: https://esc365.escardio.org/event/1803   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.   Declarations of interests Stephan Achenbach, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Haran Burri has declared to have potential conflicts of interest to report: institutional research and fellowship support or speaker honoraria from Abbott, Biotronik, Boston Scientific, Medtronic, Microport. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Isabel Deisenhofer has declared to have potential conflicts of interest to report: speaker honoraria and travel grants from Abbott Medical, Biosense-Webster, Boston Scientific, BMS, Volta Medical, and research grant (for the institution) from Abbott Medical and Daiichi Sankyo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Helmut Puererfellner has declared to have potential conflicts of interest to report: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities for the following companies: Abbott, Biotronik, Biosense Webster, Boston Scientific, Daiichi Sankyo, Medtronic. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

What is Carcinoid Heart Disease (CHD)? Which NET patients develop CHD?  Retired cardiologist and carcinoid heart disease specialist Dr. Jerome Zacks provides an overview of CHD and describes the appropriate screening, diagnosis, and treatment. MEET DR. JEROME ZACKSDr. Jerome Zacks is a Cardiologist/Carcinoid Heart Disease Specialist; retired since December of 2021; but remain active as Associate Clinical Professor of Medicine at the Icahn Medical School at Mount Sinai in New York City and founding member of the Center for Carcinoid and Neuroendocrine Tumors at the Icahn Medical School at Mount Sinai; founder of the Carcinoid Heart Center; formerly on the Medical Advisory Board of the Carcinoid Cancer Foundation;  currently head the Electrocardiography course for the 4th Year Medical Student elective at the Mt. Sinai Medical Center which has resulted in an international reputation among students seeking Cardiology training in the United States.  He has expertise in matters of health care Insurance Carriers' theft of funds from the Medicare program, has studied patterns of abuse in the Medicaid program and has extensive knowledge of pharmaceutical company abusive practices. Dr. Zacks continues to devote time to the care of patients with Carcinoid Heart Disease. He has served as a member of the Guidelines Committees of the European Neuroendocrine Tumor Society (ENETS) and of the North American Neuroendocrine Tumor Society (NANETS).   He developed a new approach to compression stockings for patients with leg edema; he was granted a patent for this innovation.  He has authored two national petitions urging Congress to mandate that any health care professional who uses one's license, in making decisions which influence a patient's care, be held to the SAME STANDARD OF CARE as the patient's treating professional. (These two petitions were blocked by Senator Cory Booker.)  In his role as patients' physician, he has attempted to remove barriers of communication.  His business card includes his personal mobile phone number as well as his email address and website information; He encourages patients to phone for immediate answers to urgent matters.  Along with his wife, Yelena - an RN- they have devoted their professional lives to patients with heart disease from rare Neuroendocrine tumors. They have mentored 5 children, and are now learning from them and their 6 grandchildren have provided the real fuel and excitement for their lives.For more information, visit https://www.ncf.net/podcast/43For more information, visit LACNETS.org.

Click the icon below to listen.

Today we welcome Dr. Andalib Nawab, a cardiology internist at Cardiology Associates of Schenectady, part of St. Peter's Health Partners Medical Associates.

With Giovanni Donato Aquaro, University of Pisa - Italy, and Carmelo De Gori, Fondazione Monasterio, Pisa - Italy. Link to editorial Link to paper  

You know that falling into sin is dangerous business. So if God gives us the power to overcome temptation and avoid sin, why do we still give in to sin . . . and cling to it? More important, how can you defend yourself from sin's allure? To support this ministry financially, visit: https://www.oneplace.com/donate/85/29

Click the icon below to listen.

Trials from the 2025 American College of Cardiology scientific sessions, including the WARRIOR, PROTECT TAVI, DAPATAVI, and SOUL are reviewed by John Mandrola, MD This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Thank you Comments II WARRIOR Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD Keep Fighting INOCA After Neutral WARRIOR Trial https://www.medscape.com/viewarticle/keep-fighting-inoca-after-neutral-warrior-trial-2025a10007uf III Cerebral Embolic Protection in TAVI PROTECT TAVI https://www.nejm.org/doi/full/10.1056/NEJMoa2415120 PROTECTED TAVR https://www.nejm.org/doi/full/10.1056/NEJMoa2204961 Instrumental Variables in Randomized Trials https://evidence.nejm.org/doi/10.1056/EVIDctw2400204 IV  DAPATAVI SGLT2 Inhibitors Progressing to New Standard After TAVI https://www.medscape.com/viewarticle/sglt2-inhibitors-progressing-new-standard-after-tavi-2025a100081y Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation https://www.nejm.org/doi/full/10.1056/NEJMoa2500366 V SOUL Study of Oral Semaglutide and CV outcomes in Diabetes Oral GLP-1 Receptor Agonist Reduces CV Risk https://www.medscape.com/viewarticle/oral-glp-1-receptor-antagonist-reduces-cv-risk-2025a10007kr Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes https://www.nejm.org/doi/full/10.1056/NEJMoa2501006 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

This week we review a recent work from the team at Seattle Children's Hospital about obstetrical sonography and referral of fetuses with 'suboptimal imaging' for fetal echocardiography. Should all 'suboptimal imaging' cases be referred? How can fetal cardiologists parse out who needs a fetal cardiac scan and when? How does the fetal team in Seattle practically serve a geographic region exceeding 2,000 miles and properly triage the referrals, particularly when 'suboptimal imaging' is the rationale for referral? Associate Professor of Pediatrics at The University of Washington, Dr. Bhawna Arya provides deep insights into her recent work on how to think about fetuses referred for 'suboptimal imaging' as a rationale for fetal consultation. https://doi.org/10.1007/s00246-024-03495-9

If you had a terrible disease, you would obviously want to know how to treat it. To support this ministry financially, visit: https://www.oneplace.com/donate/85/29

With Stefan Simovic, Faculty of Medical Sciences, University of Kragujevac, Kragujevac - Serbia, Stelios Tzeis, Mitera Hospital, Athens - Greece, and Natasja de Groot, Erasmus University Medical Centre, Rotterdam - The Netherlands, and Dominik Linz, Maastricht University Medical Centre (MUMC), Maastricht - The Netherlands. During this podcast Stefan Simovic, Natasja de Groot, Stylianos Tzeis and Dominik Linz will tackle the EHRA 2025 Highlights  (scientific breakthroughs, major trial results, latest news on in catheter ablation and leadless pacing). 

Howie and Harlan are joined by Alexi Nazem, a Yale-trained internist who co-founded the healthcare staffing company Nomad Health and now leads healthcare investments at AlleyCorp. Harlan reports on new research from the American College of Cardiology meeting; Howie examines the consequences of vast staffing cuts in the federal healthcare infrastructure.  Links: Research from the American College of Cardiology Meeting “Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial” “Early Intra-Aortic Balloon Support for Heart Failure-Related Cardiogenic Shock: A Randomized Clinical Trial” “Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism” Alexi Nazem The Human Genome Project Institute for Healthcare Improvement “100,000 Lives Campaign: Ten Years Later” “Continuous Improvement as an Ideal in Health Care” “The Science of Improvement” Health & Veritas Episode 145: Max Laurans: An Entrepreneurial Life in Medicine Nomad Health Yale School of Management case study: “Nomad Health: The disruption of physician staffing services" “Staffing Marketplace Nomad Health Raises $105 Million As It Expands Beyond Travel Nurses” “America Is Running Out of Nurses” “Staffing Marketplace Nomad Health Lays Off 17% Of Workforce” “Why AI deals in healthcare have grown faster than other areas of tech — and what VCs are paying close attention to” Turmoil at Federal Health Agencies “Mass Layoffs Hit Health Agencies That Track Disease and Regulate Food” “The top FDA vaccine official is forced out, cites RFK Jr.'s 'misinformation and lies'“ “NIH cuts halt 24-year program to prevent HIV/AIDS in adolescents and young adults” “Princeton's US grants frozen, follows Trump actions against other schools” “Trump Administration Abruptly Cuts Billions From State Health Services” “Texas measles outbreak grows to 90 cases, worst level in 30 years” “As Trump pursues his policies, Democratic states block his path” “Proposed foreign aid cuts could lead to millions of HIV deaths, study estimates” Learn more about the MBA for Executives program at Yale SOM. Email Howie and Harlan comments or questions.

On this episode of JHLT: The Podcast, the Digital Media Editors invite author Ioana Preston, MD, to discuss the paper, “Efficacy and safety of sotatercept across ranges of cardiac index in patients with pulmonary arterial hypertension: A pooled analysis of PULSAR and STELLAR.”   Dr. Preston is the director of the pulmonary hypertension center at Lahey Hospital and Medical Center in Burlington, Massachusetts, and has over 20 years of experience in caring for patients with PH, as well as multiple clinical trials in PH.   The episode explores: What makes sotatercept unique as the first “biologic” in the treatment of PAH Hypotheses about the mechanism of action in sotatercept Sotatercept's interaction with mPAP and what it indicates about the drug's action on the pulmonary vasculature   For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt.   Those involved in the heart failure and mechanical circulatory support should tune in again later this month for a study on apixaban plasma levels in patients with HeartMate 3 support.   Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

Biopharma's reaction to the forced resignation of venerable CBER director Peter Marks has been swift and furious, with former FDA Commissioner Robert Califf saying on LinkedIn that “the FDA as we've known it is finished.” Analysts, meanwhile, called Marks' exit “arguably biotech investors' greatest fear,” as company shares across the industry tumbled.   Marks' announcement added insult to injury for the agency, which was already reeling from the announced cuts of 10,000 employees across the Department of Health and Human Services, including 3,500 FDA staffers. Those layoffs began to roll out on Tuesday as some employees showed up to work only to discover they no longer had a job. Amid all this chaos, Cantor Fitzgerald analysts called for Kennedy himself to get the axe, saying in part that he was “undermining the trusted leadership of health care in this country.”    Despite the turmoil, drug development continues in the obesity space, with Novo Nordisk presenting mixed data from its semaglutide franchise at the American College of Cardiology's annual conference last weekend. While an oral version of the blockbuster drug showed cardiovascular benefits for some patients, it failed to change the trajectory of other major adverse cardiovascular events. Meanwhile, Novo continues its battle against compounding pharmacies manufacturing copycat versions of semaglutide—as multiple players scramble for a piece of this massive pie.    On the Alzheimer's front, Eli Lilly's Kisunla failed last week to win the recommendation of the EU's Committee for Medicinal Products for Human Use. This decision is consistent with CHMP's recent stance on anti-amyloid antibodies, as Biogen and Eisai have also struggled to get Leqembi approved in Europe.    On a positive note, pharma R&D returns grew again in 2024, but Deloitte warned that this progress is “fragile.” The firm urged companies to be bold and embrace cutting edge technology like gene therapy and AI. These returns can't help everyone, however, as the past week has seen an uptick in layoffs across biopharma, including at Carisma Therapeutics, Organon and Tenaya Therapeutics.   Finally, as April kicks off cancer conference season, BioSpace took a deep dive into the recent action in the always-hot in radiopharmaceuticals space.  

Lauren Rosenberg, a highly experienced Physician Associate, has dedicated nearly two decades to Internal Medicine and Health Optimization. Driven by a passion for preventative care, Lauren founded Vent Health to shift the focus from disease treatment to prevention. She specializes in a personalized approach that blends genetics, epigenetics, biomarkers, and lifestyle factors to tailor health interventions that extend and optimize each patient's health span. Lauren's practice includes prescribing peptides (GLP, CLP/GIP) for weight loss, insulin resistance, pre-diabetes, etc.  This episode concentrates on all the questions about GLP's, the prescription based Ozempic and others, as well as the Compound Pharmacy GLP's that can often times be less expensive.  Heather and Lauren also cover the common side effects, and how to manage them. In this episode you will learn other health benefits of these peptides, and who can benefit from them as well as practical tips for getting started on GLP-1 Therapy. Lauren is a frequent speaker at the Age Management Medicine Group (AMMG) and the American Academy of Anti-Aging Medicine (A4M) conferences.  Lauren's practice includes Cardiology prevention: Diagnostics and AI analysis to detect dangerous plaque and calcium; advanced lipid testing and cardiovascular genetics Longevity biomarkers: DNA methylation for biological age, VO2 max testing, Telomere health; Therapeutic plasma exchange Cancer prevention: methylated DNA screens, preventative MRIs, tumor marker testing. We will have Lauren back to discuss all these other longevity and optimum health subjects. This episode concentrates on the information pertaining to Peptides, GLP's etc as they are so popular right now. If you want to contact Lauren for more info, you can reach her via her site: https://myventhealth.com and go to the contact page. Or email: vent@myventhealth.com Social Media:  IG: https://www.instagram.com/iamheathert/            You Tube: https://youtube.com/@iamheathert?si=ZvI9l0bhLfTR-qdo Learn more about your ad choices. Visit megaphone.fm/adchoices

00:00 Introduction and Overview of Caristo Diagnostics09:08 The Technology Behind Carry Heart18:00 Clinical Implications and Risk Assessment27:27 Actionable Steps for Patients30:34 Optimizing Cardiovascular Drug Dosing32:31 AI in Cardiovascular Medicine33:50 Leveraging Historical Data for Risk Prediction36:25 AI's Role in Molecular Pathway Analysis39:03 GLP-1 and Cardiovascular Outcomes41:56 Targeted Therapies in Cardiovascular Treatment42:45 Building Trust in New Technologies49:16 Regulatory Approvals and Future Prospects54:15 Expanding Applications Beyond Cardiology57:16 Looking Ahead: The Future of Caristo Diagnostics 

Carolyn Thomas was having a heart attack when an emergency room doctor diagnosed her with acid reflux and sent her home. For two weeks, she continued experiencing symptoms while attempting to live normally—all while her heart was in crisis. She tells this extraordinary story of survival, and talks about how it turned her into an advocate for women's heart health. Also in this conversation: gender bias in cardiac care, why our awareness of heart diseases is actually worse than it used to be, and specific strategies women can use to advocate for themselves in medical settings. Click the 'Follow' button for more stories about women's health.----------------------------------------------------------------------------------------------------------------------------------------------Links from the episode:My Heart Sisters blog: https://myheartsisters.org/A Woman's Guide to Living with Heart Disease: https://www.press.jhu.edu/books/title/11800/womans-guide-living-heart-disease---------------------------------------------------------------------------------------------------------------------------------------------- New to Overlooked? Welcome! Overlooked was launched in 2023 to tell the story of ovarian cancer through one woman's story. In 2024 the show started to cover all kinds of other overlooked topics in women's health - and there are many. The show is hosted by Golda Arthur, an audio journalist and producer. See why Overlooked is an award-winning podcast by taking a listen to our back catalog. LIKE WHAT YOU HEAR? Support Overlooked on Patreon, and get rewards like merch, the ability to send in questions for expert guests, and a 'backstage pass' to the show. GET ON THE LIST for the newsletter to learn the backstory to the episodes, and join a community of people who are deeply engaged with women's health topics. Sign up here: https://overlookedpodcast.kit.com/e4b85028b6 EMAIL US: hello@overlookedpod.com FOLLOW US:Instagram https://www.instagram.com/overlookedpod/LinkedIn https://www.linkedin.com/company/105541285/admin/dashboard/ LEARN MORE: https://overlookedpod.com/ DISCLAIMER What you hear and read on ‘Overlooked' is for general information purposes only and represents the opinions of the host and guests. The content on the podcast and website should not be taken as medical advice. Every person's body is unique, so please consult your healthcare professional for any medical questions that may arise.

The wide array of cardiovascular implantable electronic devices (CIEDs) s may lead to confusion as to which one to use in what circumstances. Differentiating defibrillators, pacemakers, and loop recorders--as well as accessing and utilizing the collected data--is covered by guest Erin Nordstrom, BSN, RN, PHN, CV-B. Related PCNA courses:Choosing the Right Cardiac Pacing Device: https://pcna.net/online-course/choosing-the-right-cardiac-pacing-device-heart-failure-interventions/ 12-Lead ECG in the Clinical Setting: https://pcna.net/online-course/interpreting-and-applying-the-12-lead-ecg-in-clinical-settings/Managment of Atrial Fibrillation: https://pcna.net/online-course/management-of-atrial-fibrillation-from-a-to-z/ See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send us a textRollin McCraty, PhD is Psychophysiologist & Director of Research at the HeartMath Institute where his primary areas of focus are the mechanisms by which emotions influence cognitive processes, behavior, health, & global interconnectivity between people & Earth's energetic systems. His research has appeared in journals including the American Journal of Cardiology, Journal of the American College of Cardiology & Stress Medicine and Biological Psychology. In this episode, you'll hear the critical difference between heart rate & heart rate variability, the frequency connection between earth & earthlings, how to measure your personal field environment & how heart coherence is steroids for your intuition.Guest: https://store.heartmath.org/inner-balance-coherence-plus.html  Coupon Code TOP1 | https://www.heartmath.org/ | https://www.heartmath.com/addheartpodcast/ | https://www.instagram.com/heartmath/ | https://www.instagram.com/rollin_mccraty/ | https://www.facebook.com/HeartMath/ | https://www.linkedin.com/company/heartmath-lnc/ Host:  https://www.meredithforreal.com/  | https://www.instagram.com/meredithforreal/  | meredith@meredithforreal.com | https://www.youtube.com/meredithforreal  | https://www.facebook.com/meredithforrealthecuriousintrovert Sponsors: https://www.jordanharbinger.com/starterpacks/ | https://uwf.edu/university-advancement/departments/historic-trust/ 

In this episode, Dr. Valentin Fuster presents key findings from the April 8, 2025 issue of the Journal of the American College of Cardiology, covering three groundbreaking studies. Topics include the newly defined threshold for mild aortic stenosis using MRI, the relationship between heat wave exposure and cardiac mortality, and the long-term outcomes of aortic valve performance in patients undergoing TAVR versus surgery.

Heart disease is the number one killer. But what if you could know your risk factors far in advance? Some cutting-edge tests are changing the game in cardiovascular health, and they're more accessible than you might think.  In this episode, Dr. Joel Kahn sheds light on the critical role of early detection and intervention in preventing heart disease. Dr. Kahn, a leading cardiologist, emphasizes the significance of identifying atherosclerosis, the primary culprit behind heart disease, through advanced technology scans before you start feeling any symptoms.  Listen to this episode and start preventing rather than lamenting your heart health! Episode Notes Dr. Joel Kahn stresses that even individuals with seemingly healthy lifestyles can have significant plaque buildup in their arteries, highlighting the importance of regular screenings.  Benefits of Coronary Artery Calcium Scans The Coronary Artery Calcium (CAC) scan is a valuable tool for detecting plaque in the arteries, providing crucial insights into cardiovascular health. This scan is recommended for individuals at risk of heart disease, such as those with a family history of high cholesterol. Early detection through the CAC scan can help in developing preventive strategies and maintaining heart health. Detect Heart Disease Early Early detection of heart disease is crucial in preventing its potentially fatal consequences. Tools like the CAC scan and AI-assisted CT scans provide detailed information about cardiovascular health, enabling you to take proactive steps towards maintaining a healthy heart. Regular screening and early intervention can significantly improve cardiovascular health outcomes. Prevent Atherosclerosis Atherosclerosis, the buildup of plaque in arteries, is a significant factor in heart disease and other health issues like erectile dysfunction. Regular screening, including the CAC scan, can help prevent the progression of atherosclerosis. By addressing risk factors and maintaining a healthy lifestyle, you can reduce your chances of developing heart disease. Follow us on Instagram at https://www.instagram.com/feelfreakingamazing/  Guest Bio Kahn obtained a BA in 1980 and MD in 1983 from the University of Michigan. He is a Clinical Professor of Medicine at Wayne State University School of Medicine and Associate Professor of Medicine at Oakland University William Beaumont School of Medicine. He is the founder of the Kahn Center for Cardiac Longevity in Bingham Farms, Michigan. Kahn is a Fellow of the American College of Cardiology and a member of the Physicians Committee for Responsible Medicine. He has authored articles for HuffPost and the Reader's Digest. Links https://www.drjoelkahn.com/  https://www.kahnlongevitycenter.com/  Related Episodes Prevent and Reduce Heart Disease, with Dr. Joel Kahn Detect Osteoporosis & Osteopenia Early, with Kevin Ellis Replace Routine Mammographic Screenings, with Dr. Jenn Simmons  

Welcome to my podcast. I am Doctor Warrick Bishop, and I want to help you to live as well as possible for as long as possible. I'm a practising cardiologist, best-selling author, keynote speaker, and the creator of The Healthy Heart Network. I have over 20 years as a specialist cardiologist and a private practice of over 10,000 patients. In this podcast, Dr. Warrick Bishop, a cardiologist and CEO of the Healthy Heart Network, discusses the misconceptions surrounding cholesterol and its role in heart health. He emphasizes that heart disease is prevalent in Australia, with a heart attack occurring every twenty minutes, many of which could be prevented with better understanding. Dr. Bishop critiques the term "coronary artery disease," arguing that it overlooks the long-term process of atherosclerosis, which develops over decades. He highlights the importance of distinguishing between primary and secondary prevention of heart disease, noting that while cholesterol-lowering treatments are effective after an event, their role in primary prevention remains ambiguous.

Are Vaccines Good For Us? Marschall S. Runge, M.D., Ph.D., was born in Austin, Texas, and graduated from Vanderbilt University with a BA in General Biology and a PhD in Molecular Biology. He received his medical degree from the Johns Hopkins School of Medicine and trained in internal medicine at Johns Hopkins Hospital. He was a cardiology fellow and junior faculty member at Massachusetts General Hospital. Dr. Runge's next position was at Emory University, where he directed the Cardiology Fellowship Training Program. He then moved to the University of Texas Medical Branch in Galveston, where he was Chief of Cardiology and Director of the Sealy Center for Molecular Cardiology. He joined the University of North Carolina (UNC) from 2000 – 2014, where he served as Charles Addison and Elizabeth Ann Sanders Distinguished Professor of Medicine, Chair of the Department of Medicine, President of UNC Physicians and Vice Dean for Clinical Affairs. Dr. Runge visits with Mark Alyn.Become a supporter of this podcast: https://www.spreaker.com/podcast/late-night-health-radio--2804369/support.

Are Vaccines Good For Us? Marschall S. Runge, M.D., Ph.D., was born in Austin, Texas, and graduated from Vanderbilt University with a BA in General Biology and a PhD in Molecular Biology. He received his medical degree from the Johns Hopkins School of Medicine and trained in internal medicine at Johns Hopkins Hospital. He was a cardiology fellow and junior faculty member at Massachusetts General Hospital. Dr. Runge's next position was at Emory University, where he directed the Cardiology Fellowship Training Program. He then moved to the University of Texas Medical Branch in Galveston, where he was Chief of Cardiology and Director of the Sealy Center for Molecular Cardiology. He joined the University of North Carolina (UNC) from 2000 – 2014, where he served as Charles Addison and Elizabeth Ann Sanders Distinguished Professor of Medicine, Chair of the Department of Medicine, President of UNC Physicians and Vice Dean for Clinical Affairs. Dr. Runge visits with Mark Alyn.Become a supporter of this podcast: https://www.spreaker.com/podcast/late-night-health-radio--2804369/support.

Stopping oral anticoagulation after AF ablation, the core problem with paradoxes like the smoker's paradox, chronic total occlusion PCI, and an ACC/EHRA preview are discussed by John Mandrola, MD, in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Oral Anticoagulation after Successful AF Ablation Iwawakie et al https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2831851 OCEAN protocol paper https://doi.org/10.1016/j.ahj.2017.12.007 II Smoker's Paradox Presch et al https://www.jacc.org/doi/10.1016/j.jcin.2024.12.028 Gupta et al https://doi.org/10.1161/JAHA.116.003370 III CTO PCI Main sub-analysis paper Bangalore et al https://doi.org/10.1016/j.jacc.2025.01.029 DECISION CTO https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.031313 Main EURO CTO trial https://doi.org/10.1093/eurheartj/ehy220 3-year MACE of EURO CTO https://eurointervention.pcronline.com/article/three-year-outcomes-of-eurocto-a-randomized-multicentre-trial-comparing-revascularization-and-optimal-medical-therapy-for-chronic-total-coronary-occlusions EXPLORE https://www.jacc.org/doi/abs/10.1016/j.jacc.2016.07.744 ISCHEMIA CTO https://www.clinicaltrials.gov/study/NCT03563417   IV ACC and EHRA Preview Mandrola's 5 Trials to Look for at the 2025 American College of Cardiology Scientific Sessions https://www.medscape.com/viewarticle/mandrolas-5-trials-look-2025-american-college-cardiology-2025a10006zu You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

This week we review a recent PHTS study on long-term outcomes following heart transplantation. Why do patients develop coronary vasculopathy and how commonly is it seen at long term follow-up? What factors are associated with better or worse long term outcomes? How do 'adverse childhood experiences' result in worse outcomes for patients? Why do young transplant patients have better long-term outcomes and can this be leveraged to improve older patient outcomes? We speak with the first author of this week's work, Assistant Professor of Pediatrics at Ohio State and also from Nationwide Children's Hospital, Dr. Emily Hayes. DOI: 10.1111/petr.70042

In this episode, we are discussing 2 articles focused on cardiovascular genetics. In the first segment, Khalida talks to authors Marianne and Erin about their research exploring the opportunities for downstream revenue of cardiac genetic counseling services in a pediatric medical center. In the second segment, Naomi chats with Jodie and Erin about the recent NSGC Practice Resource about genetic testing and counseling for hypertrophic cardiomyopathy. Segment 1: Cardiac genetic counseling services: Exploring downstream revenue in a pediatric medical center Marianne Olson, MS, CGC is a genetic counselor at Baptist Health in Kentucky. She provides prenatal genetic counseling at Maternal Fetal Medicine clinics in Louisville and Lexington. Marianne graduated from the Cincinnati Genetic Counseling Graduate Program in 2024. Prior to working as a genetic counselor, Marianne taught high school chemistry and biology for 12 years. Erin Miller is an Associate Professor in the University of Cincinnati College of Medicine. Erin is a genetic counselor IN THE DIVISION OF CARDIOLOGY at Cincinnati Children's Hospital Medical Center. She leads the cardiology genetic counseling team in providing genetic counseling services to individuals of all ages with and at risk for cardiovascular disease. Erin is focused on improving access to genetics services for families with inherited cardiovascular diseases. In this segment we discuss: - What sparked the decision to explore downstream revenue (DSR) in a cardiac genetic counseling setting - Financial challenges institutions face when hiring genetic counselors, especially around reimbursement - The role of genetic counseling in reducing costs by guiding risk stratification and avoiding unnecessary testing - Limited uptake of cardiac screening among at-risk relative and strategies that could help improve adherence - How findings from this study can support the case for sustaining genetic counseling roles within pediatric cardiology - Potential to adapt the study's methodology to other specialties like neurology or prenatal genetics, and considerations for doing so   Segment 2: Genetic testing and counseling for hypertrophic cardiomyopathy: An evidence-based practice resource of the National Society of Genetic Counselors Erin Miller (she/her) is an Associate Professor in the College of Medicine at the University of Cincinnati and a cardiac genetic counselor at Cincinnati Children's Hospital Medical Center in the Division of Cardiology. She leads the cardiology genetic counseling team in providing genetic counseling services to individuals of all ages with and at risk for cardiovascular disease. Erin is focused on improving access to genetics services for families with inherited cardiovascular diseases. Associate Professor Jodie Ingles (she/her)  is Head of the Clinical Genomics Laboratory and Program Director of Genomics and Inherited Disease Program at Garvan Institute of Medical Research. She is a cardiac genetic counsellor in the Department of Cardiology, Royal Prince Alfred Hospital Sydney. Her team is focused on using genomics to improve diagnosis and care of families with inherited cardiovascular diseases. In this segment we discuss: - The motivation behind creating an official practice resource focused on genetic testing and counseling for HCM - Deep dive into the first major recommendation: offering genetic testing to all individuals with a suspected or confirmed diagnosis of HCM, paired with appropriate genetic counseling - Exploration of the second recommendation: ensuring that genetic tests are selected, ordered, and interpreted within the context of genetic counseling, and the complexities that come with this process - Discussion of the third recommendation: providing cardiac and cascade genetic testing to at-risk relatives, without age limitations, and why this is critical for effective family-based care - A look at the barriers to integrating genetic services into cardiology practices, especially in settings without dedicated genetics expertise   Would you like to nominate a JoGC article to be featured in the show? If so, please fill out this nomination submission form here. Multiple entries are encouraged including articles where you, your colleagues, or your friends are authors. Stay tuned for the next new episode of DNA Dialogues! In the meantime, listen to all our episodes Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Dialogues”.  For more information about this episode visit dnadialogues.podbean.com, where you can also stream all episodes of the show. Check out the Journal of Genetic Counseling here for articles featured in this episode and others.  Any questions, episode ideas, guest pitches, or comments can be sent into DNADialoguesPodcast@gmail.com.  DNA Dialogues' team includes Jehannine Austin, Naomi Wagner, Khalida Liaquat, Kate Wilson and DNA Today's Kira Dineen. Our logo was designed by Ashlyn Enokian. Our current intern is Sydney Arlen.  

Want to thrive in medical sales? In this episode, TJ, a regional business director specializing in cardiology, shares insider strategies for success—from fostering a growth mindset to mastering self-leadership. Learn how top performers refine their processes, understand their motivations, and leverage innovation to drive sales in coronary artery disease and structural heart technologies.   Discover why psychology beats tactical selling when building strong healthcare partnerships and how relationship-building is the key to long-term success. TJ also reveals how Boston Scientific onboards new reps to ensure they make an impact from day one, engaging effectively with hospital accounts.   Thinking about breaking into medical sales from a different industry? We explore how a restaurant server can successfully pivot into medical sales, the importance of demonstrating growth, and what hiring managers look for in standout candidates. Plus, get expert tips on acing interviews, crafting personalized follow-ups, and making authentic connections that lead to opportunities.   Whether you're a seasoned rep, an aspiring medical sales professional, or a leader looking to build a high-performing team, this episode is packed with real-world insights, career strategies, and actionable advice to help you succeed in the dynamic world of medical sales.   Meet the guest: TJ Jones is a Regional Sales Director for Boston Scientific, a global company that transforms lives through innovative medical solutions. He is passionate about positively impacting patient care and helping sales professionals reach new milestones professionally and personally. Connect with TJ: LinkedIn Connect with Me: LinkedIn Love the show? Subscribe, rate, review, and share! Here's How » Want to connect with past guests and access exclusive Q&As? Join our EYS Skool Community today!  

In this special episode of Health Matters, we celebrate Doctor's Day. Dr. David Slotwiner, Chief of Cardiology at NewYork-Presbyterian Queens, shares how he balances his life at the hospital with a new hobby: herding sheep with his Border Collie named Cosmo. As part of an ongoing series this year, Dr. Slotwiner is our first highlight in showcasing doctors' hobbies!___David Slotwiner, MD, is the Chief of Cardiology at NewYork-Presbyterian Queens. Dr. Slotwiner is a board certified Cardiologist specializing in Clinical Cardiac Electrophysiology practicing at NewYork-Presbyterian Queens hospital located in Flushing, NY. He received his medical degree from the University of Chicago Pritzker School of Medicine, completed his internship in Internal Medicine, residency in Cardiovascular Disease and fellowship in Clinical Cardiac Electrophysiology at NewYork-Presbyterian Hospital. Dr. Slotwiner is board certified in Cardiovascular Disease and Clinical Cardiac Electrophysiology. He specializes in heart diseases such as congenital heart defects, coronary artery disease, heart rhythm disorders, and heart failure.___Health Matters is your weekly dose of health and wellness information, from the leading experts. Join host Courtney Allison to get news you can use in your own life. New episodes drop each Wednesday.If you are looking for practical health tips and trustworthy information from world-class doctors and medical experts you will enjoy listening to Health Matters. Health Matters was created to share stories of science, care, and wellness that are happening every day at NewYork-Presbyterian, one of the nation's most comprehensive, integrated academic healthcare systems. In keeping with NewYork-Presbyterian's long legacy of medical breakthroughs and innovation, Health Matters features the latest news, insights, and health tips from our trusted experts; inspiring first-hand accounts from patients and caregivers; and updates on the latest research and innovations in patient care, all in collaboration with our renowned medical schools, Columbia and Weill Cornell Medicine. To learn more visit: https://healthmatters.nyp.org

Let's be real—entrepreneurs love the grind. Late nights, early mornings, endless coffee, and pushing the limits to build the dream. But here's the catch: if your heart isn't in peak condition, all that hustle could be cutting your time short.So, how do you level up your business without sacrificing your health?In this episode of The Happy Hustle Podcast, I sat down with Dr. Stefan Waller, a cardiologist turned health coach, to break down real strategies for optimizing heart health—without the fluff. We're talking about preventing heart disease before it even starts, simple nutrition hacks, and the key health metrics every entrepreneur should track.Dr. Waller emphasizes the importance of knowing your numbers. If you don't track your business finances, you'll go broke, right? Same thing with your health—if you don't track your key metrics, your body might be running on borrowed time.Here are two critical numbers you should be checking regularly:1️⃣ LDL Cholesterol (The Silent Killer)

In this podcast episode, Dr. Valentin Fuster, editor emeritus of the Journal of the American College of Cardiology, presents a comprehensive summary of the April 1, 2025 issue, covering five groundbreaking studies in cardiovascular research. Key highlights include insights on mechanical vs. bioprosthetic aortic valve replacement, AI-driven screening for structural heart disease, the impact of guideline-directed medical therapy in chronic coronary artery disease, and the significance of remnant cholesterol in peripheral arterial disease.

A large trial in cardiac pacing finally published, PVCs and cardiomyopathy, cannabis, CV risk and the danger of observational studies, and the tale of two disparate statin trials are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I BioPace Trial Trial manuscript https://doi.org/10.1093/europace/euaf029 II Another Belief Challenged in EP this week—PVCs and CM ‘ UC Paper https://doi.org/10.1016/j.jacep.2025.01.004 JACC Review https://doi.org/10.1016/j.jacc.2024.03.416 Lee et al https://heart.bmj.com/content/105/18/1408 III Cannabis and CV Risk Cannabis and MACE in JACC Advances: https://www.jacc.org/doi/10.1016/j.jacadv.2025.101698 Zeraatkar –Grilling the data https://doi.org/10.1016/j.jclinepi.2024.111278 PLOS-1 10.1371/journal.pone.0199705 IV Cardio-oncology Jacc Onc Substdy https://www.jacc.org/doi/10.1016/j.jaccao.2024.11.008 Editorial https://www.jacc.org/doi/10.1016/j.jaccao.2025.01.006 STOP CA JAMA 2023 https://jamanetwork.com/journals/jama/fullarticle/2807988 PREVENT https://evidence.nejm.org/doi/10.1056/EVIDoa2200097 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Women collectively “Catch Up” to men in their risk by age 60, largely because of the loss of estrogen. Based on studies from the American College of Cardiology's Annual Scientific Session (April 2024) and the American Heart Association (2013, 2023). Changes in blood pressure, cholesterol, and visceral belly fat all seem to be a part of the menopause transition for many women. Women spend 40% or more of their lives post-menopause, that's a health risk if left unchecked. Women who have an early menopause, have even more time in their lives in post menopause. Many women are advised or think about weight loss, stress reduction. Very few women think about heart health risk and muscle loss. Yet, to define cardiovascular fitness is to talk about VO2 max. VO2 max measures oxygen consumption capacity or liters of oxygen the body consumes during exercise, expressed in ml/kg/min. For every 1 liter of oxygen consumed roughly 5 kcals are burned. Two components of VO2: The delivery of oxygen The extraction of oxygen from the tissues Heart health CAN decline rapidly after menopause… All statistics are based on historically what's been true… and we sometimes forget that if we choose not to participate in the same habits of past generations we don't have to get the same results. If you lose muscle, you lose VO2. If you lose VO2, you die tired, younger, sicker and fatter. Replacing the overemphasis on cardiovascular exercise which seems to be the first go-to for women, trainers, and physicians alike, with an equal emphasis on muscle is the first step. BUT.. that negates the fact that.. muscle-building exercise improves blood sugar levels, increase strength, stamina, power to inspire and motivate greater activity Training Plan to Avoid Risk of Heart Disease Post Menopause We also train wrong for women in midlife. Highs and lows are best for women midlife. Moderate-intensity exercise, a go-to for many women since the 80s, is actually an energy drain. Instead of reducing stress, it spikes cortisol, making fat loss and recovery harder. High intensity to toleration during perimenopause, not all women tolerate when hormones are doing the greatest fluctuation. There's a dance between the muscle, heart, bone benefits and the adrenals/cortisol response that has to be done. Post menopause hormones have stabilized and a woman is likely to tolerate more high intensity- not longer but with greater frequency from say 2 times a week to up to 4. This will help overcome the loss of fast twitch muscle fibers lost more quickly with age and without fast or powerful movements. The significant boost of growth hormone and testosterone that occurs with true high intensity exercise provides mitigation of cortisol. Let's review this again. Moderate exercise can occur for 3 reasons: Intentionally you unknowingly are trying to hit moderate level exercise You attend boot camp type classes that never allow complete recovery. They feel hard and high intensity for long periods of time, but in actuality, you're not reaching your peak capacity. You start out going at a low level but you either push it because you feel good or you go longer because it feels good, both result in a cardiac drift into the “no benefits zone” of moderate intensity exercise. What's the answer? Your midlife workout formula should look like this: 80% Low Intensity (walking, recovery movement)

This week we review a recent study assessing the rate of hematochezia seen in children following neonatal congenital heart surgery, predominantly for aortic obstruction such as in HLHS. How often is this sign observed in this patient group and what percentage of these patients have actual necrotizing enterocolitis (NEC)? Are there any modifiable risk factors for NEC? How can these data help clinicians separate out those with more benign forms of hematochezia from those with NEC and how might this improve care for this patient group? These are amongst the questions reviewed this week with the work's first author, University of Michigan Assistant Professor of Pediatrics, Dr. Courtney Strohacker. DOI: 10.1007/s00246-024-03485-xFor those interested in pediatric podcasts, please take a look at this list of the 'top 15' pediatric topic podcasts - we are #4 in pediatrics for 2025!https://podcast.feedspot.com/pediatric_podcasts/

Listener feedback, resistant hypertension, K-binders for MRA use in heart failure, nutritional epidemiology, and a positive study for vitamin D are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback Califf editorial https://www.jacc.org/doi/10.1016/j.jaccas.2020.01.003 II Resistant HTN Positive Topline Results for Lorundrostat in Hypertension https://www.medscape.com/viewarticle/positive-topline-results-lorundrostat-hypertension-2025a100062e III K-Binding REALIZE K Trial https://doi.org/10.1016/j.jacc.2024.11.014 Packer Editorial https://doi.org/10.1016/j.jacc.2025.01.011 Diamond Trial EHJ https://doi.org/10.1093/eurheartj/ehac401 REALIZE K Commentary https://www.medscape.com/viewarticle/realize-k-new-potassium-binder-help-keep-spiro-board-2024a1000m2c IV Butter vs Plant-based Oils and Mortality JAMA-IM Study https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2831265 Is Red Meat Healthy? Multiverse Analysis Has Lessons Beyond Meat https://www.medscape.com/viewarticle/red-meat-healthy-multiverse-analysis-has-lessons-beyond-meat-2024a10008qv Cookbook Review https://doi.org/10.3945/ajcn.112.047142 V Vitamin D Impact Factor https://www.medscape.com/viewarticle/rare-win-vitamin-d-this-time-ms-2025a10005ul D-Lay trial https://jamanetwork.com/journals/jama/fullarticle/2831270 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net